Could a Mitochondria-Targeting pill help failing hearts?

NCT ID NCT05410873

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether MitoQ, a drug that targets cell energy centers, can improve heart function in 53 people with dilated cardiomyopathy. Participants took MitoQ or a placebo for several months while researchers measured heart energy levels and pumping ability using MRI scans. The goal was to see if reducing cell stress could help the heart work better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MitoQ (mitoquinol mesylate)

What this could lead to

If it works, this could point toward a new treatment that helps the heart work better in people with dilated cardiomyopathy.

What could go wrong

This is a small, early-phase trial with only 53 participants, so results may not apply to everyone. The drug may not improve heart function or could cause side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DILATED CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dilated cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Royal Brompton Hospital

    London, United Kingdom